(Q38712213)

English

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology

scientific article published on March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

2

object named as

L Puig

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

José Luis López Estebaranz

0 references

author name string

E Daudén

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

C Ferrándiz

3

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

J L Sánchez-Carazo

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

J M Hernanz-Hermosa

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Spanish Psoriasis Group of the Spanish Academy of Dermatology and Venereology

6

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

publication date

1 March 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Journal of the European Academy of Dermatology and Venereology

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

30 Suppl 2

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1-18

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

The Delphi method: an efficient procedure to generate knowledge.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Treatment of scalp psoriasis: review of the evidence and Delphi consensus of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Definition of treatment goals for moderate to severe psoriasis: a European consensus

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version).

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The use of tumour necrosis factor alpha-blockers in daily routine. An Austrian consensus project

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Psodisk, a new visual method for assessing the burden of psoriasis on patients.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Consensus guidelines for the management of plaque psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Strategies for improving the quality of care in psoriasis with the use of treatment goals--a report on an implementation meeting

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Critical review of generic and dermatology-specific health-related quality of life instruments

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Current severe psoriasis and the rule of tens.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

National Psoriasis Foundation clinical consensus on disease severity

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Induction phase, primary endpoint, time to decide on primary failure, and therapeutic goals in biologic treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Maximizing patient adherence for optimal outcomes in psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Combining traditional systemic and biologic therapies for psoriasis

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

A treatment strategy for psoriasis: transitioning from systemic therapy to biologic agents

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The diagnosis and treatment of early psoriatic arthritis.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

The concept of psoriasis as a systemic inflammation: implications for disease management

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis con agentes biológicos, 2013. I. Consideraciones de eficacia y selección del tratamiento

1 reference

https://api.crossref.org/works/10.1111%2FJDV.13542

21 January 2018

Identifiers

10.1111/JDV.13542

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38712213&oldid=1779559848"